The Swedish biotech company WntResearch drug candidate Foxy-5 has emerged as a possible new blockbuster in a novel cancer treatment concept targeting the lethal metastatic process by agonising the Wnt-5a signaling pathway in breast, colon and prostate cancer. http://www.infoom.se/mysite/index.php?sida=80579&user=9801
They are obviously (even the CSO confimed this last spring) in talks with Big Pharma regarding Foxy-5, and surprisingly Aug 17 in the Q2 report declared they took a small loan SEK 10 million instead of a bigger new stock emission to current stock holders for financing of the Phase II study scheduled to begin this year.
It seems that they want to gain time and put pressure on Big Pharma, possibly more than one BP...
A deal COULD be worth several times the current stock price. ATH is still far away though at SEK 79 from November 2015. The absolute risk is high but risk/reward very very good in my view and the scientific background is very strong for a project soon entering Phase II.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.